IAG’s CEO Dr. Kubassova is Speaking in the Podcast for Deep Tech Startups

IAG's CEO Dr. Kubassova is Speaking in the Podcast for Deep Tech Startups

Dr. Olga Kubassova, CEO of IAG, interview in Podcast that Gives Voice to Scientists Entrepreneurs

The CEO of IAG, Dr. Olga Kubassova, guest starred on the E² – Epistémê Entrepreneur, the podcast that gives voice to scientist entrepreneur of  deep tech companies, aired on the 19 March 2021.

‘Can mathematics, algorithms and artificial intelligence offer a superpower to radiologists for the analysis of medical images? This is the challenge that Dr. Olga Kubassova with her team of superheroes took up’, starts the host Ari Massoudi

During this interview, Dr. Kubassova talks about her path from Kazakhstan, her place of birth to the UK, where she followed her PhD studies. She speaks about the creation of IAG, Image Analysis Group from the scientific idea and turning it into a business.

Valuable expertise from the successful scientist entrepreneur on

  • discovering the commercial opportunity,
  • transferring her expertise into IAG,
  • developing IAG’s value proposition
  • … and many more awesome key points that any Scientist-Entrepreneur should note as a great teaching!

Listen here: Youtube or Anchor

About Dr. Olga Kubassova 

Dr. Olga Kubassova is a mathematician by background with MS in Mathematics from St. Petersburg State University, Russia, MS in Information Technology from Lappeenranta University of Technology, Finland and a PhD in Computer Science from the University of Leeds, UK.

Dr. Olga Kubassova is the founding scientist and CEO of IAG, Image Analysis Group, an imaging expert company. She started IAG straight after her PhD with an idea to bring the best of mathematics and computer science to optimize clinical development process while using imaging derived biomarkers to reliably and objectively assess efficacy of a novel drug.

Today IAG is a recognized partner to many blue-chip pharma companies in rheumatology, oncology and neurology. Since completing her PhD research in the area of MRI algorithm development for musculoskeletal disorders, Olga has been a significant contributor to the development of MRI as a clinical research and diagnostic tool in rheumatoid arthritis, osteoarthritis and other inflammatory joint diseases. She has co-authored over 60 articles, 7 book chapters and a number of abstracts that have built a significant evidence base for the medical imaging as a sensitive and objective biomarker for the assessment of various diseases and as an early measure of efficacy of new drugs. Olga is an active researcher, scientific adviser to the UK government and EU funding bodies, inc. European Commission, Innovative Medicines Initiative; she is an editor and reviewer of several scientific journals.

Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.

E² – Epistémê Entrepreneur 

E² gives voice to Scientist-Entrepreneurs enabling them to present their Deep Tech startups and share their valuable experience with you. E² demystifies tech entrepreneurship for you.
Our guests will tell you about their backgrounds, their motivations, the critical problems they aim to solve, the obstacles they have overcome and the future challenges they will take up.


About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin